Identification of Potent and Novel α4β1 Antagonists Using in Silico Screening

• Published in: Journal of medicinal chemistry Vol. 45; no. 14; pp. 2988 - 2993
• Main Authors: Singh, Juswinder, van Vlijmen, Herman, Liao, Yusheng, Lee, Wen-Cherng, Cornebise, Mark, Harris, Mary, Shu, I-hsiang, Gill, Alan, Cuervo, Julio H, Abraham, William M, Adams, Steven P
• Format: Journal Article
• Language: English
• Published: Washington, DC American Chemical Society 04.07.2002
• Subjects: Biological and medical sciences; Medical sciences; Pharmacology. Drug treatments; Respiratory system; Allergy; Late antigen; Vascular cell adhesion molecule 1; Non peptide compound; Antiasthma agent; Modeling; Antiallergic; Prevention; Integrin; Structure activity relation; Carboxylic acid; Molecular model; Ureas; Obstructive pulmonary disease; Antagonist; Ungulata; Biological receptor; Immunopathology; Respiratory disease; Antiinflammatory agent; Benzene derivatives; Cell adhesion molecule; In vitro; Asthma; Inhalation; Vertebrata; Chemotherapy; Three dimensional model; Experimental disease; Mammalia; Treatment; Animal; Affinity; Sheep; Artiodactyla
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm020054e

The antigen α4β1 (very late antigen-4, VLA-4) plays an important role in the migration of white blood cells to sites of inflammation. It has been implicated in the pathology of a variety of diseases including asthma, multiple sclerosis, and rheumatoid arthritis. We describe a series of potent inhibitors of α4β1 that were discovered using computational screening for replacements of the peptide region of an existing tetrapeptide-based α4β1 inhibitor (1; 4-[N‘-(2-methylphenyl)ureido]phenylacetyl-Leu-Asp-Val) derived from fibronectin. The search query was constructed using a model of 1 that was based upon the X-ray conformation of the related integrin-binding region of vascular cell adhesion molecule-1 (VCAM-1). The 3D search query consisted of the N-terminal cap and the carboxyl side chain of 1 because, upon the basis of existing structure−activity data on this series, these were known to be critical for high-affinity binding to α4β1. The computational screen identified 12 reagents from a virtual library of 8624 molecules as satisfying the model and our synthetic filters. All of the synthesized compounds tested inhibit α4β1 association with VCAM-1, with the most potent compound having an IC50 of 1 nM, comparable to the starting compound. Using CATALYST, a 3D QSAR was generated that rationalizes the variation in activities of these α4β1 antagonists. The most potent compound was evaluated in a sheep model of asthma, and a 30 mg nebulized dose was able to inhibit early and late airway responses in allergic sheep following antigen challenge and prevented the development of nonspecific airway hyperresponsiveness to carbachol. Our results demonstrate that it is possible to rapidly identify nonpeptidic replacements of integrin peptide antagonists. This approach should be useful in identification of nonpeptidic α4β1 inhibitors with improved pharmacokinetic properties relative to their peptidic counterparts.